BridgeMD
New treatment option for Advanced Malignant Solid Tumor
Official title A Study of MT027 in Patients with Pleural Malignant Tumors
ClinicalTrials.gov ID: NCT06726564
What this study is testing
What is MT027 cells suspension?
MT027 cells suspension is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for advanced malignant solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- voluntarily participate in the study and sign informed consent;
- age over 18 years old (including the cut-off value), regardless of gender;
- advanced malignant solid tumor pathologically and/or histologically diagnosed with malignant pleural effusion requiring drainage confirmed by...
- the original pleural cavity malignant tumor after standard treatment failure, or top treatment;
- signed informed consent not line within a month before the chest cavity medicine injection, but does not exclude the diagnostic puncture;
You likely can't join if
- known allergy to the study drug or its excipients;
- patients with pleural puncture contraindications or won't benefit from intrathoracic medication;
- any antineoplastic drugs other than systemic antineoplastic therapy that the subject has been taking stably and any treatment that may have an effect...
- in the first test within 2 weeks before treatment received radiotherapy.
- major surgery is performed within 4 weeks before the first trial treatment and the patient has not fully recovered;
- are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 1 week before the first trial treatment.
See the full eligibility criteria
- voluntarily participate in the study and sign informed consent;
- age over 18 years old (including the cut-off value), regardless of gender;
- advanced malignant solid tumor pathologically and/or histologically diagnosed with malignant pleural effusion requiring drainage confirmed by histopathology or cytopathology (metastatic or primary);
- the original pleural cavity malignant tumor after standard treatment failure, or top treatment;
- signed informed consent not line within a month before the chest cavity medicine injection, but does not exclude the diagnostic puncture;
- The people voluntarily provided sufficient tumor cells in the pathological section of the primary lesion and/or pleural effusion for B7-H3 expression detection, and the tumor cells in the pathological section of the...
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-2;
- within 7 days before treatment laboratory meet the following criteria: Routine blood (14 days) :
- Absolute neutrophil count (ANC) ≥1.5×109 /L;
- platelet count (PLT) or 80 x 109 / L;
- hemoglobin (HGB) or 80 g/L (allowing blood transfusion and use erythropoiesis agent). The presence of active bleeding or other ongoing conditions that result in increased red-cell destruction or impaired production may...
- total bilirubin (TIBC) or less 2 times the upper limit of the normal range (ULN);
- no liver metastasis, AST and ALT 3 x ULN or less; ALT and AST≤5 times ULN in the presence of liver metastasis; Kidney:
- Serum creatinine (Cr) ≤ 2 times ULN; Or creatinine clearance (CrCL) ≥ 50 mL/min (estimated by Cockcroft-Gault formula); Blood coagulation function:
- international standardization ratio (INR) or prothrombin time (PT) 1.3 x ULN or less;
- Partial activated thromboplastin time (APTT) ≤ 1.5 times ULN; 9) toxicity from previous systemic therapy returned to grade 1 or less or to baseline before the first dose (except alopecia); 10) Fertile men and women of...
- known allergy to the study drug or its excipients;
- patients with pleural puncture contraindications or won't benefit from intrathoracic medication;
- any antineoplastic drugs other than systemic antineoplastic therapy that the subject has been taking stably and any treatment that may have an effect on the control of pleural effusion (other than diagnostic puncture or...
- in the first test within 2 weeks before treatment received radiotherapy.
- major surgery is performed within 4 weeks before the first trial treatment and the patient has not fully recovered;
- are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 1 week before the first trial treatment.
- participated in other drug clinical trials within 4 weeks before screening;
- always had targeted B7 - H3 CAR - T cells treatment;
- patients with active systemic or pulmonary infection, coagulopathy and other major diseases;
- with severe heart, lung, liver and renal insufficiency; Cardiac function: grade 3 or above according to the New York Heart Association (NYHA) criteria; Liver function: Child - Puge classification standard for grade C or...
- patients with severe autoimmune diseases;
- recipients of previous allogeneic tissue/solid organ transplantation;
- who received a live vaccine within 2 weeks before the first cell therapy or were scheduled to receive a live vaccine during the study;
- active HBV infection; Or hepatitis C virus infection (defined as positive for HCV antibody, allowed if HCV-RNA was below the lower limit of detection); Or human immunodeficiency virus infection (defined as HIV antibody...
- people had severe neurocognitive impairment as judged by the investigator;
- pregnant or lactating women;
- There were any clinical or laboratory abnormalities or other reasons considered by the investigator to preclude participation in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.